A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jae Park, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University
New Haven, Connecticut, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (limited Protocol Activities)
Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (limited Protocol Activities)
Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Commack (limited Protocol Activities)
Commack, New York, United States
- Memorial Sloan Kettering Westchester (limited Protocol Activities)
Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Memorial Sloan Kettering Nassau (limited Protocol Activities)
Uniondale, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Feb 2018
- Primary completion
- 31 Jan 2027
- Completion
- 31 Jan 2027
- Last update posted
- 12 Feb 2026
- Registered enrollment
- 30
- Registry id
- NCT03410875
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.